Compare Regeneron Pharmaceuticals Inc (REGN) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Atlassian Corporation PLC — how do they compare? Regeneron Pharmaceuticals Inc trades at $801.51 (market cap $83.15B), while Atlassian Corporation PLC trades at $177.31 (market cap $44.99B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| REGN | TEAM | |
|---|---|---|
Market Cap | $83.15B | $44.99B |
Sector | Health | Technology |
52-Week High | $852.03 | $194.68 |
52-Week Low | $555.51 | $57.15 |
Enterprise Value | $77.86B | $44.99B |
Dividend Yield | 0.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% on the day, with a bullish technical signal from moving averages and a neutral RSI near 54. The stock shows strong profitability with a net income margin of 27.86% and consistent earnings beats in recent quarters. However, multiple class-action lawsuits filed in September 2026 allege securities fraud related to a Phase 3 clinical trial disclosure, creating near-term uncertainty.
The outlook remains cautiously optimistic given robust fundamentals and a 69% analyst buy rating, but legal overhangs and a projected earnings dip in 2026 pose risks. Upside hinges on legal resolution and pipeline execution, while downside is capped by institutional support like CalSTRS' recent $79 billion position increase.
Atlassian (TEAM) trades at $176.42, down 6.94% over 24 hours but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and a neutral RSI. Fundamentally, revenue growth is robust, climbing to $5.22B in 2025, though net income margins are negative. Recent earnings beats and AI integration into products like Rovo highlight operational strength, but high valuations and insider sales warrant caution.
Outlook is cautiously optimistic; analyst consensus is bullish with a $179.81 price target, driven by AI adoption and cloud expansion. Risks include premium valuation metrics, persistent net losses, and competitive pressures. Investors should weigh growth potential against profitability challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
